Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Albumin iodinated I-125 serum is a radiopharmaceutical diagnostic agent composed of human serum albumin labeled with the radioactive isotope iodine‑125. It is administered intravenously and used primarily for the determination of total blood and plasma volume, as well as measurement of circulation time and cardiac output. After injection, it distributes rapidly within the intravascular compartment, with slower movement into extravascular spaces. The mechanism relies on dilution principles using a known quantity of radiolabeled protein to calculate blood or plasma volume by measuring its distribution in the body. The drug is classified as a protein-based biologic therapy and functions solely as a diagnostic tool rather than having therapeutic effects[1][2][4][5][7]. Albumin iodinated I‑125 was originally developed by Mallinckrodt Medical and has been marketed under brand names such as Jeanatope[8]. It is currently manufactured by Iso-Tex Diagnostics[2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Albumin iodinated I-125 serum.